Consideration on the Research and Development of New Drugs for Rare Tumors.
10.3779/j.issn.1009-3419.2022.101.26
- Author:
Ling TANG
1
;
Yuanyuan SONG
1
;
Zhimin YANG
1
Author Information
1. Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China.
- Publication Type:Journal Article
- Keywords:
Drug;
Rare tumors;
Research and development
- MeSH:
Antineoplastic Agents/therapeutic use*;
China;
Humans;
Lung Neoplasms/drug therapy*;
Rare Diseases/drug therapy*;
Research
- From:
Chinese Journal of Lung Cancer
2022;25(7):443-447
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, China's anti-tumor drugs has shown a continuous growth trend, and the activity of anti-tumor research and development in China accounts for a higher proportion in the world. However, further analysis of research and development hotspots show that the research and development of anti-tumor drugs is uneven among different tumor types. Due to the small number of the patients, it is difficult to conduct clinical trials, resulting in less drug development in the field of rare tumors. However, patients' treatment needs will also bring potential opportunities for pharmaceutical companies. The development of basic research and the discovery of new molecular tumor typing make "rare tumors" a dynamic concept. The scope of "rare tumors" may gradually expand with the precise development of treatment; or as the knowledge of tumors gradually develops from histocytology to the molecular level, It is possible that certain tumors with specific mutations can be combined into a group of non-rare "pan-tumors". Rare tumors are characterized by both rare diseases and tumors. Its drug research and development should not only meet the requirements of tumor drug research and development, but also adapt to the characteristics of rare diseases. Therefore, in the drug research and development, we can refer to the research and development principle of rare disease drugs, combine with the characteristics of tumor diseases, make full use of non-rare tumor clinical trials, make full use of scientific tools and exquisite trial design, and realize the promotion of the research and development of rare tumor drugs. This paper will summarize the thoughts in the review of new drugs in the field of rare tumors, in order to provide guidance for the industry.
.
